🔎 Trials Near Me

Utama › Karsinoma Epitel Ovari › Virginia

Kajian klinikal Karsinoma Epitel Ovari di Virginia

6 kajian untuk Karsinoma Epitel Ovari sedang mencari peserta di lokasi di Virginia.

Bandar di Virginia

Teks kajian rasmi (Bahasa Inggeris)

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • UVA Health University Hospital /ID# 275309, Charlottesville
  • Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456, Fairfax
  • Virginia Oncology Associates- Norfolk (Brock) /ID# 275227, Norfolk
  • dan 1 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 29 Sep 2026 · NCT06890338

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Fairfax
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05867251

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  • Research Site, Fairfax
  • Research Site, Roanoke
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 21 Jul 2026 · NCT07218809

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

  • Virginia Cancer Specialists, Fairfax
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Mac 2026 · NCT06395519

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  • SCRI - Virginia Oncology Associates, Norfolk
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 23 Dis 2025 · NCT06690775

A Study of NX-1607 in Adults With Advanced Malignancies

  • University of Virginia, Charlottesville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT05107674

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.